DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2000 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ERYTHROCIN STEARATE

Summary for Tradename: ERYTHROCIN STEARATE

Patents:0
Applicants:1
NDAs:1
drug
patent expirations by year for
 ERYTHROCIN STEARATE

Clinical Trials for: ERYTHROCIN STEARATE

Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis
Status: Terminated Condition: Gastroparesis

Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
Status: Recruiting Condition: FAP-Familial Adenomatous Polyposis

Erythromycin Versus Azithromycin in Preterm Premature Rupture of Membranes
Status: Withdrawn Condition: Preterm Premature Ruptured Membranes

Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
Status: Recruiting Condition: Epidermolysis Bullosa

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)
Status: Completed Condition: Hepatitis C Virus

The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers
Status: Completed Condition: Healthy

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
Status: Completed Condition: Healthy; Renal Insufficiency

Intravenous Erythromycin Before Endoscopy in Patients With Variceal Bleeding: A Randomized, Double-Blind Trial
Status: Completed Condition: Variceal Bleeding

Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
Status: Completed Condition: Bulimia Nervosa; Eating Disorders

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
Status: Completed Condition: Blepharitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Abbott
ERYTHROCIN STEARATE
erythromycin stearate
Tablet; Oral060359Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
Abbott
ERYTHROCIN STEARATE
erythromycin stearate
Tablet; Oral060359Approved prior to Jan 1, 1982RXNo<disabled><disabled>
Abbott
ERYTHROCIN STEARATE
erythromycin stearate
Tablet; Oral060359Approved prior to Jan 1, 1982RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc